Promising stem cell therapy for atopic dermatitis
Published: June 27, 2024
Seo et al. conducted a groundbreaking Phase I/II clinical trial exploring the use of human bone marrow-derived clonal mesenchymal stem cells (hcMSCs) for the treatment of moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin condition. With the rising prevalence of AD, particularly in adults, the search for safe and effective long-term treatments is critical.
The study, as published in The Journal of Allergy and Clinical Immunology (JACI) by Seo et al., began with a Phase I trial focusing on the safety of hcMSC therapy. This phase involved 20 adult subjects with moderate-to-severe atopic dermatitis, each receiving three intravenous infusions of hcMSCs. The results showed that the treatment was well-tolerated, with no serious adverse effects, establishing a safe dosage for further research.
Phase II extended the investigation to 72 subjects in a double-blind, placebo-controlled setting. The findings revealed that subjects receiving hcMSCs experienced significantly greater improvement in their AD symptoms compared to those receiving a placebo. Notably, 57% of the hcMSC-treated subjects achieved a 50% reduction in the Eczema Area and Severity Index (EASI-50) at 12 weeks, compared to just 32% in the placebo group. The safety profile remained favorable, with most adverse events being acceptable.
In conclusion, this study presents hcMSC therapy as a promising treatment for moderate-to-severe AD, with a good safety profile and substantial efficacy. These findings support further research into the long-term benefits and underlying mechanisms of hcMSCs in managing AD.
The Journal of Allergy and Clinical Immunology (JACI) is an official scientific journal of the AAAAI, and is the most-cited journal in the field of allergy and clinical immunology.
Full Article